Register for our free email digests:
Alaric DeArment
Reporter
Writes for:
Latest From Alaric DeArment
ATAI Raises $125m Series C To Expand The Boundaries In Mental Health
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.
Regeneron COVID-19 Cocktail’s Flame To Burn Brightly But Unclear For How Long
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
ASH Data Bring UniQure Closer To Filing Hemophilia B Gene Therapy
The company plans to file with 52-week data for AMT-061 and is confident it won't face the same stringent requirements from the FDA that led to a complete response letter for BioMarin's Roctavian.
Adamis Gets Another CRL For Opioid Overdose-Reversal Drug
Adamis got its second complete response letter for Zimhi. While not apparently related to the first, it may complicate the company's outlook following a lackluster quarter.
Ionis, AstraZeneca To Use Real-World Data To Accelerate RNA-Targeting Cholesterol Drug
Early data presented at the American Heart Association showed strong PCSK9 and LDL cholesterol lowering for ION449; AstraZeneca plans rapid development under an RWE-based FDA pilot program.
Real-World Data, AI Play Key Roles In COVID-19 Vaccine Programs
RWD has helped with development of multiple SARS-CoV-2 vaccines already and could be a useful tool for the future, as panelists discussed at the AI Cures conference.